DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Clinical trial NCT06178159 · RECRUITING
Trial details
- NCT number
- NCT06178159
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-28
- Primary completion
- 2026-06-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.